# Actelion clinical trials: 143 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 143 trials with Actelion as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Actelion: 143 rows for $7.15, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/actelion

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 143
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 143, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 16, 2023 | NCT05731492 | A Study of Macitentan in Children Below 2 Years of Age | Actelion | Phase 1 | Withdrawn | Arterial Hypertension, Pulmonary | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05731492) |
| June 27, 2022 | NCT05433675 | A Study of Two Macitentan Formulations in Healthy Adult Participants | Actelion | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05433675) |
| June 22, 2022 | NCT05427162 | A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist | Actelion | Phase 1 | Completed | Pulmonary Arterial Hypertension | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05427162) |
| May 26, 2022 | NCT05392530 | A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Participants | Actelion | Phase 1 | Completed | Healthy | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05392530) |
| February 11, 2022 | NCT05236231 | A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and... | Actelion | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05236231) |
| January 5, 2022 | NCT05179876 | A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | Actelion | Phase 3 | Recruiting | Hypertension, Pulmonary | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05179876) |
| July 15, 2021 | NCT04963439 | A Study of Two Macitentan Pediatric Formulations in Healthy Adult Participants | Actelion | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04963439) |
| July 9, 2021 | NCT04955990 | A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants | Actelion | Phase 4 | Terminated | Pulmonary Arterial Hypertension | 232 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04955990) |
| June 4, 2021 | NCT04914247 | Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease | Actelion | Not applicable | Approved for marketing | Non-healing Wound, Thromboangiitis Obliterans | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04914247) |
| September 28, 2020 | NCT04565990 | A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study | Actelion | Phase 3 | Completed | Hypertension, Pulmonary | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04565990) |
| July 21, 2020 | NCT04480723 | A Study for the Identification of Biomarker Signatures for Diagnosis of Pulmonary Hypertension (PH) in Participants at Low or Intermediate... | Actelion | Early phase 1 | Completed | Hypertension, Pulmonary | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04480723) |
| June 17, 2020 | NCT04435782 | A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging | Actelion | Phase 4 | Terminated | Pulmonary Arterial Hypertension | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04435782) |
| February 18, 2020 | NCT04273945 | Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension | Actelion | Phase 3 | Active not recruiting | Pulmonary Arterial Hypertension | 935 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04273945) |
| February 17, 2020 | NCT04271475 | A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary... | Actelion | Phase 3 | Terminated | Chronic Thromboembolic Pulmonary Hypertension | 127 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04271475) |
| February 12, 2020 | NCT04266756 | A Study of Selexipag in Healthy Male Participant | Actelion | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04266756) |
| December 26, 2019 | NCT04211272 | A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants | Actelion | Phase 1 | Completed | Healthy | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04211272) |
| November 25, 2019 | NCT04175600 | A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension | Actelion | Phase 3 | Active not recruiting | Hypertension, Pulmonary | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04175600) |
| May 8, 2019 | NCT03942211 | A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag | Actelion | Phase 2 | Terminated | Sarcoidosis-associated Pulmonary Hypertension | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03942211) |
| April 10, 2019 | NCT03910621 | Safety and Efficacy of Miglustat in Chinese NPC Patients | Actelion | Phase 4 | Completed | Niemann-Pick Disease, Type C | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03910621) |
| April 5, 2019 | NCT03904693 | Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination... | Actelion | Phase 3 | Completed | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | 187 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03904693) |
| January 18, 2019 | NCT03809650 | A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension... | Actelion | Phase 3 | Terminated | Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03809650) |
| December 14, 2018 | NCT03775421 | An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients. | Actelion | Phase 3 | Terminated | Congenital Heart Disease With Fontan Circulation | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03775421) |
| October 22, 2018 | NCT03714815 | A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection... | Actelion | Phase 2 | Terminated | Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03714815) |
| September 28, 2018 | NCT03689244 | A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is... | Actelion | Phase 3 | Terminated | Chronic Thromboembolic Pulmonary Hypertension | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03689244) |
| April 12, 2018 | NCT03496506 | A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects | Actelion | Phase 1 | Completed | Healthy Subjects | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03496506) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 29 |
| Phase 2 | 27 |
| Phase 2/3 | 4 |
| Phase 3 | 54 |
| Phase 4 | 16 |
| Not applicable | 1 |
| Observational | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 105 |
| Terminated | 29 |
| Withdrawn | 4 |
| Active not recruiting | 3 |
| Approved for marketing | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pulmonary Arterial Hypertension | 59 |
| Hypertension, Pulmonary | 22 |
| Scleroderma, Systemic | 9 |
| Idiopathic Pulmonary Fibrosis | 6 |
| digital ulcers | 6 |
| Clostridium Infections | 5 |
| Multiple Sclerosis | 5 |
| Lung Diseases, Interstitial | 4 |
| Scleroderma, Diffuse | 4 |
| Pulmonary Fibrosis | 3 |
| Eisenmenger Complex | 3 |
| Anemia, Sickle Cell | 3 |
| Motor Activity | 2 |
| Niemann-Pick Disease, Type C | 2 |
| Glioblastoma | 2 |
| Hypertension | 2 |
| Heart Defects, Congenital | 2 |
| Cystic Fibrosis | 2 |
| Univentricular Heart | 1 |
| Raynaud Disease | 1 |
| Psoriasis | 1 |
| Sarcoidosis | 1 |
| Sclerosis | 1 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Thromboangiitis Obliterans | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Charter schools in the United States](https://specstream.ai/data/businesses/charter-schools/united-states)
- [Drive thru bars in the United States](https://specstream.ai/data/businesses/drive-thru-bars/united-states)
- [Footwear wholesalers in the United States](https://specstream.ai/data/businesses/footwear-wholesalers/united-states)
- [Industrial cleaning companies in the United States](https://specstream.ai/data/businesses/industrial-cleaning-companies/united-states)
- [Medical sciences schools in the United States](https://specstream.ai/data/businesses/medical-sciences-schools/united-states)
- [Periodontics practices in the United States](https://specstream.ai/data/businesses/periodontics-practices/united-states)
